Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) is scheduled to be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect Aquestive Therapeutics to post earnings of ($0.09) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link. Aquestive Therapeutics […]
Aquestive Therapeutics (NASDAQ:AQST – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Friday, Benzinga reports. They currently have a $9.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 116.35% from the stock’s previous close. A number […]
Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) and Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation. Analyst Recommendations This is a summary of […]
Reiterates commencement of pivotal pharmacokinetic (PK) study for Anaphylm™ (epinephrine) Sublingual Film expected in fourth quarter 2023 with topline data.
Wedbush reiterated their outperform rating on shares of Aquestive Therapeutics (NASDAQ:AQST – Free Report) in a research report released on Tuesday morning, Benzinga reports. Wedbush currently has a $4.00 target price on the stock. A number of other analysts have also commented on AQST. JMP Securities reissued a market outperform rating and issued a $8.00 […]